Managing rising GLP-1 costs: balancing innovation, affordability, and access

As healthcare costs continue to increase and the demand for innovative drugs rises steadily, one thing is certain: pharmaceutical spend is a top priority for benefits leaders.
In a recent survey(1), 92% of employers reported being concerned, or very concerned, about high-cost drugs in the pipeline, and 91% were concerned, or very concerned, about their overall pharmacy cost trend.
The rise in employee demand for GLP-1s, along with their high costs—estimated at around $8,000 to $10,000 per patient annually—is making employers think critically about the balancing act between managing spend and taking advantage of innovations and advancements—while taking care of their people.
In this on-demand webinar, we'll discuss emerging market trends around GLP-1s, effective strategies to manage costs, and introduce the new Collective Health + Noom Med with SmartRx program—a comprehensive solution for weight management that delivers cost savings, sustainable weight loss, and lasting health outcomes for employees.